Related Experiment Video
Updated: Apr 18, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
BTP2, a store-operated calcium channel inhibitor, attenuates morphine antinociceptive tolerance in rats
Weibo Xiao1, Feng Xiao2, Yingying Zhang3
1Department of Anesthesiology, Loudi Central Hospital, Loudi, China.
Introduction:
Morphine antinociceptive tolerance remains a critical problem in the clinical management of pain. Spinal cord glial cell activation and neuroinflammation appear to play a crucial role in the development and maintenance of this tolerance. BTP2, a potent store-operated calcium channel inhibitor, has anti-inflammatory properties in the central nervous system. This study aimed to investigate the effect of BTP2 on the development of morphine antinociceptive tolerance and glial cell-derived pro-inflammatory cytokines production by chronic morphine treatment.
Methods:
A rat model of morphine antinociceptive tolerance was made by intrathecal injection of morphine (15 μg/d). Two separate studies were conducted: Firstly, to investigate whether BTP2 could attenuate the development of tolerance, BTP2 (2 and 10 nmol) was given intrathecally 30 min before each intrathecal delivery of morphine for consecutive 7 days. Secondly, to investigate whether BTP2 could reverse the established tolerance, BTP2 administration was initiated on day 8 after 7 days of morphine treatment and continued for 4 days.
Results:
The results showed that BTP2 not only attenuated the development of morphine tolerance but also partially reversed the established tolerance. Immunohistochemistry revealed that chronic morphine-induced activation of astrocytes in the spinal cord, while BTP2 was shown to suppress the activation of astrocytes. Moreover, the administration of BTP2 alleviated the activation of astrocytic ERK and the production of proinflammatory cytokines (e.g., TNF-α and Il-1β) in the spinal cord.
Discussion:
These findings suggest that BTP2 can be a potential therapeutic drug for morphine antinociceptive tolerance, and the store-operated calcium channel may play an important role in morphine antinociceptive tolerance.
Insights
BTP2, a store-operated calcium channel inhibitor, reduces morphine tolerance by suppressing spinal cord inflammation and astrocyte activation. This offers a potential new treatment for chronic pain management.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Morphine antinociceptive tolerance is a significant clinical challenge.
- Spinal cord glial cell activation and neuroinflammation are implicated in morphine tolerance.
- BTP2, a store-operated calcium channel inhibitor, exhibits anti-inflammatory effects in the central nervous system.
Purpose of the Study:
- To investigate BTP2's effect on morphine antinociceptive tolerance development.
- To assess BTP2's impact on glial cell-derived pro-inflammatory cytokines.
- To explore BTP2's potential in reversing established morphine tolerance.
Main Methods:
- A rat model of morphine antinociceptive tolerance was established via intrathecal morphine.
- BTP2 was administered intrathecally to either prevent or reverse morphine tolerance.
- Immunohistochemistry and cytokine analysis were used to assess spinal cord changes.
Main Results:
- BTP2 attenuated the development of morphine tolerance.
- BTP2 partially reversed established morphine tolerance.
- BTP2 suppressed chronic morphine-induced astrocyte activation, ERK activation, and pro-inflammatory cytokine production (TNF-α, Il-1β).
Conclusions:
- BTP2 demonstrates potential as a therapeutic agent for morphine antinociceptive tolerance.
- Store-operated calcium channels play a crucial role in morphine antinociceptive tolerance.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Receptors: Overview
Opioid Analgesics: Morphine and Other Natural Cogeners
Pain

